BUYINS.NET: FLML, NVTL, CHDX, INCY, GERN, IMMU Are Seasonally Ripe To Go Down In the Next Five Weeks
(M2 PressWIRE Via Acquire Media NewsEdge) BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Flamel Technologies SA (NASDAQ:FLML), Novatel Wireless Inc (NASDAQ:NVTL), Chindex International Inc (NASDAQ:CHDX), Incyte Corp (NASDAQ:INCY), Geron Corp (NASDAQ:GERN), Immunomedics Inc (NASDAQ:IMMU) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
The following stocks are expected to go Down:
Symbol Company Expected Return Odds By The Following Date
FLML Flamel Technologies SA -11.29% 92.31% (12 of 13) Thursday, March 14th 2013
NVTL Novatel Wireless Inc -13.27% 91.67% (11 of 12) Monday, February 25th 2013
CHDX Chindex International Inc -11.23% 90.91% (10 of 11) Tuesday, March 12th 2013
INCY Incyte Corp -5.92% 92.31% (12 of 13) Wednesday, February 20th 2013
GERN Geron Corp -17.43% 84.62% (11 of 13) Monday, March 11th 2013
IMMU Immunomedics Inc -5.97% 84.62% (11 of 13) Tuesday, February 19th 2013
Flamel Technologies SA (NASDAQ:FLML) - Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer based technology in the United Kingdom, Ireland, the United States, France, and Europe. The company develops nanogel Medusa technology, which is intended to provide controlled release following injection of therapeutic proteins, peptides, and other molecules; a microparticle adaptation of the Medusa platform that is intended for use in the delivery of smaller proteins and peptides; and Micropump technology, a microparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology, an adaptation based on Micropump technology, which is intended to minimize the misuse and abuse of medications subject to abuse. Its principal product based on Micropump technology is Coreg CR, which is intended for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. The company s products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus and as a immune response; and FT-105, an injectable insulin formulation for diabetic patients. Its products based on its Micropump technology comprise LiquiTime for the elderly and pediatric patient patients, or others who have difficulty swallowing. The company has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; and Pfizer Inc, as well as has a joint development agreement with Digna Biotech, S.L. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France..
Novatel Wireless Inc (NASDAQ:NVTL) - Novatel Wireless, Inc. provides wireless broadband access solutions for the mobile communications market worldwide. It operates in two segments, Mobile Computing Products and machine-to-machine (M2M) Products and Solutions. The Mobile Computing Products segment offers MiFi Intelligent Mobile Hotspots, which provide connectivity option for Wi-Fi-enabled devices, such as the iPad, Kindle, tablets, PCs, MP3 players, and gaming devices; USB and PC-Card modems for wireless access; and embedded modules for use in laptop PCs, netbooks, tablets, and other electronic products to provide wireless broadband access. This segment also offers MobiLink mobile communications software suite, an object-oriented application that enables access to connectivity features, such as SMS, multimedia messaging, and virtual private networking, as well as provides video telephony and wireless local area networks management capabilities; and MiFi DLNA Server, which operates on MiFi hotspots and enables user to access and play movies, music, and photos. It serves wireless operators, laptop PC and other original equipment manufacturers, distributors, and various companies in other vertical markets. The M2M Products and Solutions segment provides asset-management solutions utilizing wireless technology and M2M communications devices. It offers Spider MT, SA, and AT integrated solutions and accessories for monitoring and managing mobile and fixed assets, vehicle tracking and telemetric, and workforce tracking and management; Enabler III and HS embedded solutions for various products or equipment to communicate with other computers; and N4A software and design services, including software and design services primarily for asset management solutions. This segment serves transportation companies, industrial companies, manufacturers of medical devices and geographical-location aware devices, and providers of security systems. The company was founded in 1996 and is headquartered in San Diego, California..
Chindex International Inc (NASDAQ:CHDX) - Chindex International, Inc. provides healthcare services in China and internationally. The company owns and operates the United Family Healthcare network of private care hospitals and ambulatory clinics in Beijing, Shanghai, Tianjin, and Guangzhou. It offers various inpatient and outpatient healthcare services, such as 24/7 emergency rooms, intensive care units and neonatal intensive care units, operating rooms, clinical laboratories, radiology, and blood banking services. The company through its joint venture, Chindex Medical Limited, markets, distributes, and sells medical equipment, medical devices, and consumables in China and Hong Kong. It also provides products in the areas of diagnostic ultrasound systems, robotic surgical systems, women s health imaging systems, and aesthetic laser systems. The company was founded in 1981 and is headquartered in Bethesda, Maryland..
Incyte Corp (NASDAQ:INCY) - Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company offers JAKAFI, an oral janus associated kinase inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. The company s product pipe line includes INCB18424, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies. The company s products in pipeline also comprise INCB28050 that is in Phase IIb clinical trail for the treatment rheumatoid arthritis and psoriasis; INCB28060 and INCB24360, which are Phase I clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware..
Geron Corp (NASDAQ:GERN) - Geron Corporation, a biopharmaceutical company, develops therapies for cancer. Its clinical development product candidates include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, thrombocythemia, and myeloma. The company was founded in 1990 and is based in Menlo Park, California..
Immunomedics Inc (NASDAQ:IMMU) - Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. Its products include epratuzumab, which is in Phase III trials for the treatment of systemic lupus erythematosus in non-Hodgkin lymphoma and acute lymphoblastic leukemia; Yttrium-90-labeled clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that completed a Phase I/II clinical trials; Veltuzumab, a Phase II clinical study completed product for the treatment of patients with non-Hodgkin s lymphoma and immune thrombocytopenic purpura. The company s early Phase clinical trial products comprise Milatuzumab, a transmembrane protein product, which is in Phase I study for antibody-drug conjugate therapy; Yttrium-90-labeled epratuzumab tetraxetan, a radiolabeled antibody product candidate, in Phase I/II study for patients with non-Hodgkin lymphoma; Labetuzumab-SN-38, which is in Phase I study in patients with colorectal cancer; hRS7-SN-38, a clinical development stage product for breast, cervix, colon and rectum, lung, pancreas, ovary, and prostate cancers. It also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers; and markets and sells a diagnostic imaging product, LeukoScan to determine infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has license and collaboration agreements with Nycomed GmbH; UCB, S.A.; and GE Healthcare LTD. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to firstname.lastname@example.org)).
(c) 2013 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]